DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team

5039Background: Genomic alterations in DNA repair genes are present in approximately 20-30% of patients with mCRPC. t-SCNC may be increasing in prevalence and is associated with adverse clinical ou...